{"pmid":32433343,"title":"Impact of the COVID-19 Pandemic on the Management of End-Stage Renal Disease Patients.","text":["Impact of the COVID-19 Pandemic on the Management of End-Stage Renal Disease Patients.","A novel infectious disease, Coronavirus disease -2019 (COVID-19), spread globally since Dec. 2019. Without effective treatment and vaccination, the strategies to restrain this disease is only keeping social distance, maintaining personal hygiene, quarantine and isolation. However, thrice-a-week treatment is inevitable for all hemodialysis patients. In addition to the high risk of cluster infection and compromised immunity in patients with end-stage renal disease (ESRD), an atypical disease presentation could also make the medial system neglect these patients during CVOID-19 pandemic. To avoid COVID-19 transmission among dialysis patients, the major societies of nephrology around the world have provided their guidelines of screening, dialysis facilities adjustment, and health education, respectively. In this review, we summarized the main contents and difference of these guidelines and addressed the prompt management for ESRD patients to reduce the risk of infection during COVID-19 pandemic.","J Chin Med Assoc","Li, Szu-Yuan","Tang, Yu-Shuo","Chan, Yu-Jiun","Tarng, Der-Cherng","32433343"],"abstract":["A novel infectious disease, Coronavirus disease -2019 (COVID-19), spread globally since Dec. 2019. Without effective treatment and vaccination, the strategies to restrain this disease is only keeping social distance, maintaining personal hygiene, quarantine and isolation. However, thrice-a-week treatment is inevitable for all hemodialysis patients. In addition to the high risk of cluster infection and compromised immunity in patients with end-stage renal disease (ESRD), an atypical disease presentation could also make the medial system neglect these patients during CVOID-19 pandemic. To avoid COVID-19 transmission among dialysis patients, the major societies of nephrology around the world have provided their guidelines of screening, dialysis facilities adjustment, and health education, respectively. In this review, we summarized the main contents and difference of these guidelines and addressed the prompt management for ESRD patients to reduce the risk of infection during COVID-19 pandemic."],"journal":"J Chin Med Assoc","authors":["Li, Szu-Yuan","Tang, Yu-Shuo","Chan, Yu-Jiun","Tarng, Der-Cherng"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433343","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/JCMA.0000000000000356","topics":["Prevention"],"weight":1,"_version_":1667342288318103554,"score":9.490897,"similar":[{"pmid":32222713,"pmcid":"PMC7179539","title":"A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease.","text":["A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease.","Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease with an alarming case fatality rate up to 5%. The risk factors for severe presentations are concentrated in patients with chronic kidney disease, particularly patients with end-stage renal disease (ESRD) who are dialysis dependent. We report the first US case of a 56-year-old nondiabetic male with ESRD secondary to IgA nephropathy undergoing thrice-weekly maintenance hemodialysis for 3 years, who developed COVID-19 infection. He has hypertension controlled with angiotensin receptor blocker losartan 100 mg/day and coronary artery disease status-post stent placement. During the first 5 days of his febrile disease, he presented to an urgent care, 3 emergency rooms, 1 cardiology clinic, and 2 dialysis centers in California and Utah. During this interval, he reported nausea, vomiting, diarrhea, and low-grade fevers but was not suspected of COVID-19 infection until he developed respiratory symptoms and was admitted to the hospital. Imaging studies upon admission were consistent with bilateral interstitial pneumonia. He was placed in droplet-eye precautions while awaiting COVID-19 test results. Within the first 24 h, he deteriorated quickly and developed acute respiratory distress syndrome (ARDS), requiring intubation and increasing respiratory support. Losartan was withheld due to hypotension and septic shock. COVID-19 was reported positive on hospital day 3. He remained in critical condition being treated with hydroxychloroquine and tocilizumab in addition to the standard medical management for septic shock and ARDS. Our case is unique in its atypical initial presentation and highlights the importance of early testing.","Am J Nephrol","Ferrey, Antoney J","Choi, Grace","Hanna, Ramy M","Chang, Yongen","Tantisattamo, Ekamol","Ivaturi, Kaushik","Park, Elisa","Nguyen, Lawrence","Wang, Brian","Tonthat, Sam","Rhee, Connie M","Reddy, Uttam","Lau, Wei Ling","Huang, Susan S","Gohil, Shruti","Amin, Alpesh N","Hsieh, Lanny","Cheng, Timmy T","Lee, Richard A","Kalantar-Zadeh, Kamyar","32222713"],"abstract":["Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease with an alarming case fatality rate up to 5%. The risk factors for severe presentations are concentrated in patients with chronic kidney disease, particularly patients with end-stage renal disease (ESRD) who are dialysis dependent. We report the first US case of a 56-year-old nondiabetic male with ESRD secondary to IgA nephropathy undergoing thrice-weekly maintenance hemodialysis for 3 years, who developed COVID-19 infection. He has hypertension controlled with angiotensin receptor blocker losartan 100 mg/day and coronary artery disease status-post stent placement. During the first 5 days of his febrile disease, he presented to an urgent care, 3 emergency rooms, 1 cardiology clinic, and 2 dialysis centers in California and Utah. During this interval, he reported nausea, vomiting, diarrhea, and low-grade fevers but was not suspected of COVID-19 infection until he developed respiratory symptoms and was admitted to the hospital. Imaging studies upon admission were consistent with bilateral interstitial pneumonia. He was placed in droplet-eye precautions while awaiting COVID-19 test results. Within the first 24 h, he deteriorated quickly and developed acute respiratory distress syndrome (ARDS), requiring intubation and increasing respiratory support. Losartan was withheld due to hypotension and septic shock. COVID-19 was reported positive on hospital day 3. He remained in critical condition being treated with hydroxychloroquine and tocilizumab in addition to the standard medical management for septic shock and ARDS. Our case is unique in its atypical initial presentation and highlights the importance of early testing."],"journal":"Am J Nephrol","authors":["Ferrey, Antoney J","Choi, Grace","Hanna, Ramy M","Chang, Yongen","Tantisattamo, Ekamol","Ivaturi, Kaushik","Park, Elisa","Nguyen, Lawrence","Wang, Brian","Tonthat, Sam","Rhee, Connie M","Reddy, Uttam","Lau, Wei Ling","Huang, Susan S","Gohil, Shruti","Amin, Alpesh N","Hsieh, Lanny","Cheng, Timmy T","Lee, Richard A","Kalantar-Zadeh, Kamyar"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222713","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1159/000507417","keywords":["acute respiratory distress syndrome","end-stage renal disease","novel coronavirus disease 19","rennin-angiotensin-aldosterone system blockade","viral sepsis"],"locations":["US","California","Utah","Losartan"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","tocilizumab","Losartan"],"topics":["Case Report"],"weight":1,"_version_":1666138490223460352,"score":282.90207},{"pmid":32391234,"pmcid":"PMC7205364","title":"A Hemodialysis Patient with Severe COVID-19 Pneumonia.","text":["A Hemodialysis Patient with Severe COVID-19 Pneumonia.","Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a novel coronavirus that has spread rapidly, resulting in a worldwide pandemic. Even though end-stage renal disease (ESRD) patients are particularly susceptible to COVID-19 infection and can develop severe to critical disease, there are limited studies and case reports about COVID-19 in ESRD patients. We report a case of a 63-year-old gentleman with ESRD on regular hemodialysis. We describe the clinical presentation of this patient, the diagnostic process, the laboratory and imaging investigations, as well as the course of treatment. He positively responded to a 14-day course of Lopinavir-Ritonavir, Ribavirin, Azithromycin, and Hydroxychloroquine.","Cureus","Alalwan, Adel A","Taher, Abdulraqeeb","Alaradi, Ali H","32391234"],"abstract":["Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a novel coronavirus that has spread rapidly, resulting in a worldwide pandemic. Even though end-stage renal disease (ESRD) patients are particularly susceptible to COVID-19 infection and can develop severe to critical disease, there are limited studies and case reports about COVID-19 in ESRD patients. We report a case of a 63-year-old gentleman with ESRD on regular hemodialysis. We describe the clinical presentation of this patient, the diagnostic process, the laboratory and imaging investigations, as well as the course of treatment. He positively responded to a 14-day course of Lopinavir-Ritonavir, Ribavirin, Azithromycin, and Hydroxychloroquine."],"journal":"Cureus","authors":["Alalwan, Adel A","Taher, Abdulraqeeb","Alaradi, Ali H"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391234","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.7759/cureus.7995","keywords":["coronavirus","covid-19","hemodialysis"],"locations":["Ribavirin","Azithromycin","Hydroxychloroquine"],"e_drugs":["Ribavirin","lopinavir-ritonavir drug combination","Azithromycin","Hydroxychloroquine"],"topics":["Case Report"],"weight":1,"_version_":1666528579967516672,"score":238.45232},{"pmid":32489502,"pmcid":"PMC7239583","title":"COVID-19 and Renal Failure: Challenges in the Delivery of Renal Replacement Therapy.","text":["COVID-19 and Renal Failure: Challenges in the Delivery of Renal Replacement Therapy.","Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first officially reported in December 2019 in Wuhan City, Hubei province, China, and has since lead to a pandemic. Most cases result in minor symptoms such as cough, fever, sore throat, myalgia, fatigue, nausea, diarrhea, loss of smell, and abdominal pain. As of April 8, 2020, more than 1,485,000 cases of COVID-19 have been reported in more than 200 countries and territories, resulting in over 90,000 deaths. Outcomes are worse in elderly patients, particularly males, and those with comorbidities, but can affect any age group. The incidence of acute kidney injury in patients with COVID-19 infection is about 3-15%; and in patients with severe infection requiring care in the intensive care unit, the rates of acute kidney injury increased significantly from 15% to 50%. Acute kidney injury is an independent risk factor for mortality in COVID-19 patients. The nephrologists, as well as intensivists, are facing immense daily challenges while providing care for these patients in the inpatient setting as well as end-stage renal disease patients on chronic dialysis in both inpatient and outpatient settings. In the current review article, we discussed the epidemiology and etiology of acute kidney injury, management of acute kidney injury including renal replacement therapy options (both hemodialysis and peritoneal dialysis) for inpatient floor, as well as intensive care unit settings. We also discussed the challenges faced by the outpatient dialysis units with COVID-19 infection. We discussed measures required to limit the spread of infection, as well as summarized the guidance as per the Centers for Disease Control and Prevention (CDC), American Society of Nephrology (ASN), American Society of Diagnostic and Interventional Nephrology (ASDIN) and the Vascular Access Society of the Americas (VASA).","J Clin Med Res","Adapa, Sreedhar","Aeddula, Narothama Reddy","Konala, Venu Madhav","Chenna, Avantika","Naramala, Srikanth","Madhira, Bhaskar Reddy","Gayam, Vijay","Balla, Mamtha","Muppidi, Vijayadershan","Bose, Subhasish","32489502"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first officially reported in December 2019 in Wuhan City, Hubei province, China, and has since lead to a pandemic. Most cases result in minor symptoms such as cough, fever, sore throat, myalgia, fatigue, nausea, diarrhea, loss of smell, and abdominal pain. As of April 8, 2020, more than 1,485,000 cases of COVID-19 have been reported in more than 200 countries and territories, resulting in over 90,000 deaths. Outcomes are worse in elderly patients, particularly males, and those with comorbidities, but can affect any age group. The incidence of acute kidney injury in patients with COVID-19 infection is about 3-15%; and in patients with severe infection requiring care in the intensive care unit, the rates of acute kidney injury increased significantly from 15% to 50%. Acute kidney injury is an independent risk factor for mortality in COVID-19 patients. The nephrologists, as well as intensivists, are facing immense daily challenges while providing care for these patients in the inpatient setting as well as end-stage renal disease patients on chronic dialysis in both inpatient and outpatient settings. In the current review article, we discussed the epidemiology and etiology of acute kidney injury, management of acute kidney injury including renal replacement therapy options (both hemodialysis and peritoneal dialysis) for inpatient floor, as well as intensive care unit settings. We also discussed the challenges faced by the outpatient dialysis units with COVID-19 infection. We discussed measures required to limit the spread of infection, as well as summarized the guidance as per the Centers for Disease Control and Prevention (CDC), American Society of Nephrology (ASN), American Society of Diagnostic and Interventional Nephrology (ASDIN) and the Vascular Access Society of the Americas (VASA)."],"journal":"J Clin Med Res","authors":["Adapa, Sreedhar","Aeddula, Narothama Reddy","Konala, Venu Madhav","Chenna, Avantika","Naramala, Srikanth","Madhira, Bhaskar Reddy","Gayam, Vijay","Balla, Mamtha","Muppidi, Vijayadershan","Bose, Subhasish"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489502","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.14740/jocmr4160","keywords":["acute kidney injury","covid-19","end-stage renal disease","hemodialysis","hemofiltration","kidney impairment","peritoneal dialysis","renal replacement therapy"],"locations":["Wuhan","Hubei","China","myalgia","fatigue","diarrhea"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1668623433623142401,"score":227.8854},{"pmid":32408730,"title":"Korean clinical practice guidelines for preventing transmission of coronavirus disease 2019 (COVID-19) in hemodialysis facilities.","text":["Korean clinical practice guidelines for preventing transmission of coronavirus disease 2019 (COVID-19) in hemodialysis facilities.","Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease that is caused by the novel virus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). COVID-19 has become pandemic since December 2019, when the first case developed in Wuhan, China. Patients receiving hemodialysis are more vulnerable to viral transmission because their immune functions are impaired and they receive treatment within a narrow space. Calling on previous experience with Middle East Respiratory Syndrome during the 2015 outbreak, the joint committee of the Korean Society of Nephrology and the Korean Society of Dialysis Therapy quickly formed a COVID-19 task force team to develop a manual before the first index case was diagnosed in the hemodialysis unit. This special article introduces clinical practice guidelines to prevent secondary transmission of COVID-19 within hemodialysis facilities, which were developed to protect patients, healthcare workers, and caregivers from this highly transmissible virus. The areas of infection control covered by these guidelines include standard precautions, performing dialysis therapy for confirmed or suspected cases, performing cohort isolation for contact patients, and disease monitoring and contact surveillance. We hope these guidelines help healthcare workers and hemodialysis patients around the world cope with the COVID-19 pandemic.","Kidney Res Clin Pract","Park, Hayne Cho","Kim, Do Hyoung","Yoo, Kyung Don","Kim, Yang-Gyun","Lee, Sang-Ho","Yoon, Hye Eun","Kim, Dong Ki","Kim, Seong Nam","Kim, Myeong Sung","Jung, Yoon Chul","Kim, Yon Su","Lee, Young-Ki","32408730"],"abstract":["Coronavirus disease 2019 (COVID-19) is a highly contagious viral disease that is caused by the novel virus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). COVID-19 has become pandemic since December 2019, when the first case developed in Wuhan, China. Patients receiving hemodialysis are more vulnerable to viral transmission because their immune functions are impaired and they receive treatment within a narrow space. Calling on previous experience with Middle East Respiratory Syndrome during the 2015 outbreak, the joint committee of the Korean Society of Nephrology and the Korean Society of Dialysis Therapy quickly formed a COVID-19 task force team to develop a manual before the first index case was diagnosed in the hemodialysis unit. This special article introduces clinical practice guidelines to prevent secondary transmission of COVID-19 within hemodialysis facilities, which were developed to protect patients, healthcare workers, and caregivers from this highly transmissible virus. The areas of infection control covered by these guidelines include standard precautions, performing dialysis therapy for confirmed or suspected cases, performing cohort isolation for contact patients, and disease monitoring and contact surveillance. We hope these guidelines help healthcare workers and hemodialysis patients around the world cope with the COVID-19 pandemic."],"journal":"Kidney Res Clin Pract","authors":["Park, Hayne Cho","Kim, Do Hyoung","Yoo, Kyung Don","Kim, Yang-Gyun","Lee, Sang-Ho","Yoon, Hye Eun","Kim, Dong Ki","Kim, Seong Nam","Kim, Myeong Sung","Jung, Yoon Chul","Kim, Yon Su","Lee, Young-Ki"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32408730","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.23876/j.krcp.20.046","keywords":["covid-19","hemodialysis units","infection control","practice guideline"],"locations":["Wuhan","China","Korean"],"countries":["Korea, Republic of","China"],"countries_codes":["KOR|Korea, Republic of","CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666897319161757696,"score":218.09789},{"pmid":32488686,"pmcid":"PMC7266651","title":"Role of point-of-care ultrasound during the COVID-19 pandemic: our recommendations in the management of dialytic patients.","text":["Role of point-of-care ultrasound during the COVID-19 pandemic: our recommendations in the management of dialytic patients.","COVID-19 is a viral disease due to the infection of the novel Corona virus SARS-CoV-2, that has rapidly spread in many countries until the World Health Organization declared the pandemic from March 11, 2020. Elderly patients and those affected by hypertension, diabetes mellitus, and chronic pulmonary and cardiovascular conditions are more susceptible to present more severe forms of COVID-19. These conditions are often represented in dialytic renal end-stage patients. Moreover, dialysis patients are more vulnerable to infection due to suppression of the immune system. Growing evidences, although still supported by few publications, are showing the potential utility of ultrasound in patients with COVID-19. In this review, we share our experience in using point-of-care ultrasound, particularly lung ultrasound, to indicate the probability of COVID-19 in patients with end-stage renal disease treated by hemodialysis. We also propose recommendations for the application of lung ultrasound, focused echocardiography and inferior vena cava ultrasound in the management of patients in hemodialysis.","Ultrasound J","Vieira, Ana Luisa Silveira","Pazeli Junior, Jose Muniz","Bastos, Marcus Gomes","32488686"],"abstract":["COVID-19 is a viral disease due to the infection of the novel Corona virus SARS-CoV-2, that has rapidly spread in many countries until the World Health Organization declared the pandemic from March 11, 2020. Elderly patients and those affected by hypertension, diabetes mellitus, and chronic pulmonary and cardiovascular conditions are more susceptible to present more severe forms of COVID-19. These conditions are often represented in dialytic renal end-stage patients. Moreover, dialysis patients are more vulnerable to infection due to suppression of the immune system. Growing evidences, although still supported by few publications, are showing the potential utility of ultrasound in patients with COVID-19. In this review, we share our experience in using point-of-care ultrasound, particularly lung ultrasound, to indicate the probability of COVID-19 in patients with end-stage renal disease treated by hemodialysis. We also propose recommendations for the application of lung ultrasound, focused echocardiography and inferior vena cava ultrasound in the management of patients in hemodialysis."],"journal":"Ultrasound J","authors":["Vieira, Ana Luisa Silveira","Pazeli Junior, Jose Muniz","Bastos, Marcus Gomes"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32488686","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1186/s13089-020-00177-4","keywords":["covid-19","covid-19 pandemic","dialysis","sars-cov-2","ultrasound"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1668892169407037440,"score":181.85962}]}